Amarin Corporation plc
AMRNHealthcareNASDAQDrug Manufacturers - General · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Amarin Corporation plc (AMRN) is listed under Drug Manufacturers - General. Valued at $292.3M, AMRN is a micro-cap name in its sector. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Market Cap
$292.3M
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
14.22
EPS (TTM)
$-1.57
EPS (Fwd)
$0.98
ROE
-7.3%
ROA
-0.5%
Cash
$307.8M
Total Debt
$7.7M
Free CF
$2.2M
52W Change
-11.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $307.8M in cash comfortably exceeding the $7.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $2.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -7.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $583.2M (2021) to $213.6M (2025), a 63% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AMRN.